In summary, the work described above addresses the relevance (or lack thereof) of Bcl-2 as a potential therapeutic target. In addition, we describe a new approach that combines RNAi and gene ...

The proto-oncogene bcl-2 is known as an anti-apoptotic gene that confers the ability to block neuronal cell death after transient ischemia. In order to examine whether the bcl-2 gene can be used ...

Chemotherapy might or might not work depending on the composition of the Bcl-2 gene family, say researchers with the Walter and Eliza Hall Institute, Australia. Any cancer drug targeting those ...

The gene encoding B-cell lymphoma-2 (BCL-2) is highly expressed in many hematological malignancies, making it a promising target. Two abstracts presented at the 64th American Society of Hematology ...

Physiology : The BCL2 (B-cell lymphoma 2) gene codes for a protein that regulates ... Mutations in the BCL gene have been identified as a cause for cancers, especially lymphomas and breast cancer.

In particular, they focused on a gene called Bcl 2, known to keep melanocytes healthy. If they could find a way to interrupt the gene's actions, perhaps they could block the growth of melanomas.

Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor ...

New York, USA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight DelveInsight’s BCL-2 Inhibitor Market Insights report ...

In the May Nature Immunology Thomas Mitchell and colleagues from the National Jewish Medical and Research Center, Denver show that adjuvants may improve survival of activated T cells via induction of ...